dc.contributor.author |
Mwakigonja, A.R. |
|
dc.contributor.author |
Kaaya, E.E. |
|
dc.contributor.author |
Heiden, T. |
|
dc.contributor.author |
Wannhoff, G. |
|
dc.contributor.author |
Castro, J. |
|
dc.contributor.author |
Pak, F |
|
dc.contributor.author |
Porwit, A. |
|
dc.contributor.author |
Biberfeld, P. |
|
dc.date.accessioned |
2013-02-11T13:18:23Z |
|
dc.date.available |
2013-02-11T13:18:23Z |
|
dc.date.issued |
2010 |
|
dc.identifier.citation |
Mwakigonja, A. R., Kaaya, E. E., Heiden, T., Wannhoff, G., Castro, J., Pak, F., ... & Biberfeld, P. (2010). Tanzanian malignant lymphomas: WHO classification, presentation, ploidy, proliferation and HIV/EBV association. BMC cancer, 10(1), 344. |
|
dc.identifier.issn |
1471-2407/10/344 |
|
dc.identifier.uri |
http://hdl.handle.net/123456789/282 |
|
dc.description.abstract |
Background: In Tanzania, the International Working Formulation [WF] rather than the WHO Classification is still
being used in diagnosing malignant lymphomas (ML) and the biological characterization including the HIV/EBV
association is sketchy, thus restraining comparison, prognostication and application of established therapeutic
protocols.
Methods: Archival, diagnostic ML biopsies (N = 336), available sera (N = 35) screened by ELISA for HIV antibodies
and corresponding clinical/histological reports at Muhimbili National Hospital (MNH) in Tanzania between 1996 and
2006 were retrieved and evaluated. A fraction (N = 174) were analyzed by histopathology and
immunohistochemistry (IHC). Selected biopsies were characterized by flow-cytometry (FC) for DNA ploidy (N = 60)
and some by in-situ hybridization (ISH) for EBV-encoded RNA (EBER, N = 37).
Results: A third (38.8%, 109/281) of the ML patients with available clinical information had extranodal disease
presentation. A total of 158 out of 174 biopsies selected for immunophenotyping were confirmed to be ML which
were mostly (84. 8%, 134/158) non-Hodgkin lymphoma (NHL). Most (83.6%, 112/134) of NHL were B-cell
lymphomas (BCL) (CD20+), of which 50.9%, (57/112) were diffuse large B-cell (DLBCL). Out of the 158 confirmed
MLs, 22 (13.9%) were T-cell [CD3+] lymphomas (TCL) and 24 (15.2%) were Hodgkin lymphomas (HL) [CD30+].
Furthermore, out of the 60 FC analyzed ML cases, 27 (M:F ratio 2:1) were DLBCL, a slight majority (55.6%, 15/27)
with activated B-cell like (ABC) and 45% (12/27) with germinal center B-cell like (GCB) immunophenotype. Overall,
40% (24/60) ML were aneuploid mostly (63.0%, 17/27) the DLBCL and TCL (54.5%, 6/11). DNA index (DI) of FCanalyzed
ML ranged from 1.103-2.407 (median = 1.51) and most (75.0%) aneuploid cases showed high (>40%) cell
proliferation by Ki-67 reactivity. The majority (51.4%, 19/37) of EBER ISH analyzed lymphoma biopsies were positive.
Of the serologically tested MLs, 40.0% (14/35) were HIV positive, mostly with high (≥40.0%) Ki-67 reactivity.
Conclusions: According to the 2001 WHO Classification, most subtypes are represented in Tanzanian ML.
Extranodal presentation was common among MNH lymphoma patients who also showed high aneuploidy, tumor
proliferation (KI-67) and EBER positivity. DLBCL was frequent and phenotype heterogeneity appeared similar to
observations in Western countries suggesting applicability of established intervention approaches. HIV was
apparently associated with high ML cell proliferation but extended studies are needed to clarify this. |
en_GB |
dc.language.iso |
en |
en_GB |
dc.publisher |
BioMed Central |
en_GB |
dc.relation.ispartofseries |
BMC Cancer;10:344 |
|
dc.subject |
Tanzania |
en_GB |
dc.subject |
malignant |
en_GB |
dc.subject |
lymphomas |
en_GB |
dc.subject |
WHO |
en_GB |
dc.subject |
ploidy |
en_GB |
dc.subject |
proliferation |
en_GB |
dc.subject |
HIV |
en_GB |
dc.subject |
EBV |
en_GB |
dc.title |
Tanzanian malignant lymphomas: WHO classification, presentation, ploidy, proliferation and HIV/EBV association |
en_GB |
dc.type |
Article |
en_GB |